Skip to main content

Advertisement

Archived Comments for: Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity

Back to article

  1. Autoimmune Quantum Biophysical Semeiotic Constitution is the condio sine qua non of Celiac Disease.

    Sergio Stagnaro, Quantum Biophysical Semeiotics Research Laboratory

    28 March 2011

    Editors,
    I find the paper A. Fasano's et al. "Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity", in Journal current issue, really interesting and fascinating (1).
    In addition, regarding CD bedside diagnosis, the majority of Authors are now in agreement with a pathophysiological mechanism, autoimmune in origin, as Quantum Biophysical Semeiotics have corroborated (2-8). As a matter of fact, in my 55 year-long clinical experience, all patients, I have diagnosed and treated, either were, or are, positive for Autoimmune Constitution, characterized by microcirculatory remodelling in synthesising antibody tissues, as BALT, GALT, spleen, Cerebral Associated Lymphatic Tissue (CALT), I have discovered and described earlier (2-5), and especially sub-hepatic lymphonodes, as far as CD is concerned. Interestingly, without Autoimmune Quantum Biophysical Semeiotic Constitution there is no autoimmune disorders (2-5). Every quantum-biophysical-semeiotic constitutions, including the autoimmune one, is dependent of an original mitochondrial cytopathy, I have discovered 32 years ago, and I have illustrated in numerous papers with the term Congenital Acidosic Enzyme- Metabolic Histangiopathy (2-11).
    Fortunately, physicians can noadays bedside recognize in a quantitative way, starting from individual's birthday, both these constitutions and constitution-dependent, INHERITED Real Risk, in our case of autimmune disorders, characterized by microcirculatory remodeling localised in well defined biological system, wherein the specific disease will possibly occur (9-15). In turn, microcirculatory remodelling is characterized by newborn-pathological, type I, subtype a) ONCOLOGICAL, and b) aspecific Endoarteriolar Blocking Devices in arterioles, according to Hammersen (11). Such as original knowledge proved to be reliable and useful in my clinical experience, as far as primary prevention of most common and severe disorders, like diabetes, CVD (15), dyslipidemias, hypertension, Pre-Metabolic and Metabolic Syndrome (15), osteoporosis, cancer.(2-15).
    When applied on very large scale, since birth, these new concepts of Medicine will ameliorate in paramount way the Primary Prevention of CD and C Sensitivity disorders, today s growing epidemics.

    References.
    1) Anna Sapone, Karen M Lammers, Vincenzo Casolaro, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Medicine 2011, 9:23doi:10.1186/1741-7015-9-23.
    2) Stagnaro S., Sindrome percusso-ascoltatoria autoimmune. Gazz. Med. It. 142, 555, 1983
    3) Stagnaro S., Polimialgia Reumatica Acuta Benigna Variante. Clin. Ter. 118, 193, 1986 [MEDLINE]
    4) Stagnaro Sergio. Bedside Recognizing Asthmatic Lung Disorder. Medical News Today. 9 November, 2008. http://www.medicalnewstoday.com/youropinions.php?opinionid=34250
    5) Stagnaro S., Auscultatory Percussion of Rheumatic Diseases. X European Congress of Rheumatology. Moscow. 26 June-July,1983. Proceedings, pg 175
    6) Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico- Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Travel Factory, Roma, 2004. http://www.travelfactory.it
    7)Stagnaro S., Stagnaro-Neri M., Single Patient Based Medicine.La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory, Roma, 2005. http://www.travelfactory.it
    8) Stagnaro Sergio. Single Patient Based Medicine: its paramount role in Future Medicine. Public Library of Science, 2005. http://medicine.plosjournals.org/perlserv/?request=read-response
    9) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/ 8) Stagnaro S., Istangiopatia Congenita Acidosica Enzimo-Metabolica. Gazz Med. It. Asch. Sci, Med. 144, 423, 1985
    11) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, www.travelfactory.it, Roma, 2009.
    12) Stagnaro S., West PJ., Hu FB., Manson JE., Willett WC. Diet and Risk of Type 2 Diabetes. N Engl J Med. 2002 Jan 24;346(4):297-298. [Medline]
    13) Stagnaro Sergio. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr. 2007 Feb 7; [MEDLINE]
    15) Stagnaro Sergio. CAD Inherited Real Risk, Based on Newborn- Pathological, Type I, Subtype B, Aspecific, Coronary Endoarteriolar Blocking Devices. Diagnostic Role of Myocardial Oxygenation and Biophysical-Semeiotic Preconditioning. www.athero.org, 29 April, 2009 http://www.athero.org/commentaries/comm907.asp

    Competing interests

    None declared

Advertisement